Jacobs Levy Equity Management, Inc Mersana Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.2 Billion
- Q2 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 1,332,945 shares of MRSN stock, worth $36.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,332,945
Previous 1,333,124
0.01%
Holding current value
$36.6 Million
Previous $453,000
11.92%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding MRSN
# of Institutions
40Shares Held
62.3MCall Options Held
34.3KPut Options Held
14K-
Nextech Invest Ag12.1MShares$331 Million3.22% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$230 Million0.0% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC904KShares$24.8 Million0.64% of portfolio
-
Clari Vest Asset Management LLC San Diego, CA500KShares$13.7 Million0.09% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL232KShares$6.37 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $2.67B
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...